Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (10235)	10/29/2002 2:15:55 PM
From: tuck	Read Replies (1) \| Respond to of 57110

There might be a bit of downside to Benchpress's bioshort picks. I own SEPR but recently hedged it. SEPR has prioritized their programs to reduce burn, and make their debt burden easier to carry until some of their pipe hits the market. Scrips of their marketed drugs -- particularly Xopenex -- have been very good recently, and I don't know if that is priced in. HGSI is a tough call; their financial position is not as bad as Sterling made it out to be, and Sterling has a pretty sorry reputation. I'd be tempted to go long again under ten bucks, but I still don't like their pipeline. Benchpress has made some solid short calls; no disrespect, just adding a few thoughts. I might throw in CVTX (not being too forthcoming about late stage clinical results with their lead compound), AGIX (hypy management), and AFFX. I actually like AFFX, but it is pretty richly valued; a buy in the teens, but vulnerable in the mid twenties. ABI on any bounce: I think it has a tough future. Mass spec biz is crowded, though still pretty good. Assays on demand has stiff competition from Sequenom and others. Sequencing business is mature, and different, better methods are on the horizon. edit: despite restructuring, I see ABGX as the most dangerous short listed. Though near term upside isn't huge, I don't think the downside is, either. Cheers, Tuck